GW Pharma Responds: ‘Not Creating a Monopoly’

British drug manufacturer GW Pharma and its American subsidiary, Greenwich BioSciences, have responded to Leafly’s report last week about the company’s attempts to move proprietary cannabidiol (CBD) bills through at least two state legislatures.

GW/Greenwich says it is not opposing medical marijuana or CBD access. Continue reading “GW Pharma Responds: ‘Not Creating a Monopoly’”